AGL

ANGLE PLC ORD 10P

TitleTime
Business UpdateTue 28/04/20 | 07:00
Parsortix performance in head and neck cancerFri 17/04/20 | 07:00
COVID-19 BUSINESS IMPACT UPDATETue 31/03/20 | 07:00
Assessing risk of brain metastasis in lung cancerTue 03/03/20 | 07:00
Data demonstrates key advantages of ParsortixMon 17/02/20 | 07:00
Issue of EquityMon 03/02/20 | 09:10
Interim ResultsThu 30/01/20 | 07:00
Change of accounting reference dateThu 30/01/20 | 07:00
Successful face-to-face meeting with FDAWed 22/01/20 | 07:00
Notice of ResultsWed 08/01/20 | 12:33
Issue of EquityMon 23/12/19 | 09:55
Result of AGMWed 30/10/19 | 14:44
Q-submission to FDA containing headline dataWed 30/10/19 | 07:00
Notice of AGMTue 08/10/19 | 07:00
Holding(s) in CompanyFri 04/10/19 | 17:54
Research with Parsortix in prostate cancerTue 10/09/19 | 07:00
Initiation of Ovarian Cancer StudyThu 29/08/19 | 07:00
Prelim Results for the year ended 30 April 2019Wed 31/07/19 | 07:00
Holding(s) in CompanyTue 16/07/19 | 09:19
Result of General Meeting anf Total Voting RightsFri 12/07/19 | 10:22
Notice of Preliminary Results and WebcastFri 28/06/19 | 13:37
Holding(s) in CompanyFri 28/06/19 | 13:08
Result of PlacingTue 25/06/19 | 17:19
Accelerated bookbuild to raise £18.0mTue 25/06/19 | 08:02
Parsortix used to investigate immunotherapy targetFri 21/06/19 | 07:00
Completion of Ovarian Cancer Pre-StudyWed 05/06/19 | 07:00
Positive Results from FDA Clinical StudyFri 31/05/19 | 07:00
IMMUNE SUPPRESSOR CELLS PROMOTE METASTASISFri 26/04/19 | 07:00
AACR 2019Thu 04/04/19 | 07:00
Holding(s) in CompanyMon 11/03/19 | 07:00
ENROLMENT COMPLETE FOR FDA CLINICAL STUDYThu 07/03/19 | 07:00
FIRST SUBJECTS ENROLLED IN OVARIAN CANCER STUDYThu 28/02/19 | 07:00
CUSTOMER DEMONSTRATES NEW USE FOR PARSORTIXMon 25/02/19 | 07:00
Research into role of immune cells in cancerMon 11/02/19 | 07:00
Interim ResultsThu 31/01/19 | 07:00
Second Price Monitoring ExtnFri 11/01/19 | 14:05
Price Monitoring ExtensionFri 11/01/19 | 14:00
Second Price Monitoring ExtnFri 11/01/19 | 11:05
Price Monitoring ExtensionFri 11/01/19 | 11:00
Second Price Monitoring ExtnFri 11/01/19 | 09:05
Price Monitoring ExtensionFri 11/01/19 | 09:00
Second Price Monitoring ExtnThu 10/01/19 | 16:41
Price Monitoring ExtensionThu 10/01/19 | 16:36
BREAKTHROUGH CANCER RESEARCH USING PARSORTIXThu 10/01/19 | 16:01
Notice of ResultsWed 09/01/19 | 07:00
Issue of LTIP Options and Share OptionsFri 21/12/18 | 07:00
Holding(s) in CompanyTue 13/11/18 | 17:10
Acquisition of outstanding sharesMon 05/11/18 | 07:00
Price Monitoring ExtensionFri 02/11/18 | 14:00
Appointment of Dr Jan Groen as NEDThu 01/11/18 | 07:00
Result of AGMTue 30/10/18 | 16:21
PARSORTIX SHOWS CAPABILITY TO HARVEST FETAL CELLSMon 29/10/18 | 07:00
Good Progress with FDA StudiesThu 25/10/18 | 07:00
Notice of AGMTue 09/10/18 | 07:00
Preliminary Results for year ended 30 April 2018Wed 25/07/18 | 07:00
EIS/VCT Advance Assurance and Total Voting RightsTue 24/07/18 | 17:42
Result of General MeetingWed 18/07/18 | 10:34
Notice of Preliminary ResultsMon 02/07/18 | 07:00
Results of FundraisingMon 25/06/18 | 18:20
Close of Accelerated BookbuildMon 25/06/18 | 14:58
Proposed Placing of New Ordinary SharesMon 25/06/18 | 07:50
ENCOURAGING PROGRESS IN ANG-002 FDA CLINICAL STUDYMon 04/06/18 | 07:00
Breakthrough Research with ParsortixThu 19/04/18 | 07:00
First patient enrolled in FDA studyThu 05/04/18 | 07:00
Price Monitoring ExtensionMon 26/03/18 | 16:35
Research UpdateMon 26/03/18 | 07:00
ANGLE plc: RESEARCH GRANT FROM ABBOTTTue 06/02/18 | 07:00
Interim ResultsWed 31/01/18 | 07:00
Notice of ResultsWed 10/01/18 | 10:16
ANGLE plc:Prostate cancer ARV7 treatment biomarkerMon 08/01/18 | 07:00
Holding(s) in CompanyWed 27/12/17 | 11:49
Transfer of Lock-in SharesTue 12/12/17 | 07:00
PARSORTIX POTENTIAL IN METASTATIC BREAST CANCERFri 08/12/17 | 07:00
PHILIPS COLLABORATION IN BREAST AND RECTAL CANCERThu 23/11/17 | 07:00
Holding(s) in CompanyFri 17/11/17 | 16:06
Total Voting Rights and Covington SubscriptionThu 16/11/17 | 08:23
Holding(s) in CompanyMon 06/11/17 | 07:00
Holding(s) in CompanyMon 06/11/17 | 07:00
Holding(s) in CompanyMon 06/11/17 | 07:00
Holding(s) in CompanyThu 02/11/17 | 10:04
ANGLE: Completion of Fundraising and AcquisitionWed 01/11/17 | 08:12
Result of AGMTue 31/10/17 | 14:18
Result of General MeetingMon 30/10/17 | 10:31
Total Voting RightsThu 26/10/17 | 08:10
Parsortix harvests cancer cells from bone marrowMon 23/10/17 | 07:00
Notice of AGMFri 20/10/17 | 15:05
Proposed further subscription for £2.8 millionThu 12/10/17 | 07:00
CTCs harvested with Parsortix grown in laboratoryMon 09/10/17 | 07:02
Potential new analytical protocol using ParsortixMon 09/10/17 | 07:01
Results of FundraisingThu 05/10/17 | 11:46
Acquisition and FundraisingThu 05/10/17 | 07:00
Holding(s) in CompanyWed 13/09/17 | 17:36
Exclusive worldwide option over megakaryocyte IPWed 13/09/17 | 07:00
Co-Marketing Partnership with QIAGENMon 11/09/17 | 07:00
Change of AdviserTue 05/09/17 | 07:00
Preliminary ResultsThu 27/07/17 | 07:00
Notice of ResultsThu 06/07/17 | 10:05
Successful Headline Data in Ovarian Cancer StudiesTue 04/07/17 | 07:00
Parsortix breakthrough in prostate cancerThu 15/06/17 | 07:00